HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Van Cutsem, Eric; Bang, Yung‐Jue; Feng, Feng-yi; Xu, Jian; Lee, Keun-Wook; Jiao, Shunchang; León Chong, J.; I. López-Sanchez, Roberto; Price, Timothy; Gladkov, Oleg; Stoß, Oliver; Hill, Julie; Ng, Vivian; Lehle, Michaela; Thomas, Marlène; Kiermaier, Astrid; Rüschoff, Josef

doi:10.1007/s10120-014-0402-y

Public

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Published in Gastric Cancer • Jul 19, 2014

Authors:

Eric Van Cutsem

Yung‐Jue Bang

Feng-yi Feng

Abstract

BACKGROUND: In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry (IHC) 3+/fluorescence in situ hybridization-positive] gastric/g...

Subject

Trastuzumab

Medicine

Immunohistochemistry

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!